<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0009">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Borgio</surname>
    <given-names>J. F.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Alsuwat</surname>
    <given-names>H. S.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Al Otaibi</surname>
    <given-names>W. M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Ibrahim</surname>
    <given-names>A. M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Almandil</surname>
    <given-names>N. B.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Al Asoom</surname>
    <given-names>L. I.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Salahuddin</surname>
    <given-names>M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kamaraj</surname>
    <given-names>B.</given-names>
   </name>, &amp; 
   <name name-style="western">
    <surname>AbdulAzeez</surname>
    <given-names>S.</given-names>
   </name>
  </person-group> (
  <year>2020</year>). 
  <article-title>State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2</article-title>. 
  <source>
   <italic>Archives of Medical Science : Ams</italic>
  </source>, 
  <volume>16</volume>(
  <issue>3</issue>), 
  <fpage>508</fpage>â€“
  <lpage>518</lpage>. 
  <pub-id pub-id-type="doi">10.5114/aoms.2020.94567</pub-id>
  <pub-id pub-id-type="pmid">32399096</pub-id>
 </mixed-citation>
</ref>
